share_log

Castle Biosciences Reports Preliminary 2024 Results: Expects $320M-$330M In Annual Revenue (+50% YoY), 96,071 Total Tests Delivered (+36% YoY), And $293M In Cash And Investments

Benzinga ·  Jan 13 08:09
  • 2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023
  • Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023
  • Year-end 2024 cash, cash equivalents and marketable investment securities expected to be approximately $293 million
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 227

Recommended

Write a comment